Display options
Cite
Anderson MS, Nadkarni A, Cardwell LA, et al. Spotlight on brimonidine topical gel 0.33% for facial erythema of rosacea: safety, efficacy, and patient acceptability. Patient Prefer Adherence. 2017;11:1143-1150doi: 10.2147/PPA.S115708.
Anderson, M. S., Nadkarni, A., Cardwell, L. A., Alinia, H., & Feldman, S. R. (2017). Spotlight on brimonidine topical gel 0.33% for facial erythema of rosacea: safety, efficacy, and patient acceptability. Patient preference and adherence, 111143-1150. https://doi.org/10.2147/PPA.S115708
Anderson, Michael S, et al. "Spotlight on brimonidine topical gel 0.33% for facial erythema of rosacea: safety, efficacy, and patient acceptability." Patient preference and adherence vol. 11 (2017): 1143-1150. doi: https://doi.org/10.2147/PPA.S115708
Anderson MS, Nadkarni A, Cardwell LA, Alinia H, Feldman SR. Spotlight on brimonidine topical gel 0.33% for facial erythema of rosacea: safety, efficacy, and patient acceptability. Patient Prefer Adherence. 2017 Jul 06;11:1143-1150. doi: 10.2147/PPA.S115708. eCollection 2017. PMID: 28740369; PMCID: PMC5505675.
Copy Download .nbib Format: NLM
Share it on

Patient Prefer Adherence. 2017 Jul 06;11:1143-1150. doi: 10.2147/PPA.S115708. eCollection 2017.

Spotlight on brimonidine topical gel 0.33% for facial erythema of rosacea: safety, efficacy, and patient acceptability.

Patient preference and adherence

Michael S Anderson, Anish Nadkarni, Leah A Cardwell, Hossein Alinia, Steven R Feldman

Affiliations

  1. Department of Dermatology, Center for Dermatology Research.
  2. Department of Pathology.
  3. Department of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA.

PMID: 28740369 PMCID: PMC5505675 DOI: 10.2147/PPA.S115708

Abstract

BACKGROUND: Brimonidine tartrate is a highly selective alpha 2 agonist that induces direct vasoconstriction of small arteries and veins, thereby reducing vasodilation and edema.

OBJECTIVE: To review the current literature regarding the safety, efficacy, and patient acceptability of brimonidine 0.33% gel.

METHODS: A PubMed search was performed using the terms brimonidine 0.33% gel, rosacea, safety, efficacy, and acceptability. Peer-reviewed clinical trials and case reports from 2012 to 2016 were screened for inclusion of safety, efficacy, and/or patient acceptability data.

RESULTS: Brimonidine topical gel 0.33% is associated with mild, transient skin-related adverse reactions. Efficacy may be achieved within 30 minutes of administration with maximal reductions in erythema 3-6 hours after administration. Patient satisfaction with use of brimonidine topical gel is superior to vehicle gel for facial appearance, treatment effect, facial redness, and daily control of facial redness.

LIMITATIONS: Studies were typically limited to 1-year follow-up. Only one study has examined the use of brimonidine topical gel in combination with other rosacea and acne medications.

DISCUSSION: Brimonidine topical gel 0.33% is a safe, effective, and patient-accepted treatment for facial erythema of rosacea.

Keywords: adverse reactions; patient satisfaction; side effects

Conflict of interest statement

Disclosure Dr Steven R Feldman has received research, speaking, and/or consulting support from a variety of companies, including Galderma, GSK/Stiefel, Almirall, Leo Pharma, Baxter, Boeringer Ingelhei

References

  1. Br J Dermatol. 2013 Sep;169(3):555-62 - PubMed
  2. J Eur Acad Dermatol Venereol. 2013 Nov;27(11):1336-43 - PubMed
  3. Br J Dermatol. 2007 Sep;157(3):474-81 - PubMed
  4. N Engl J Med. 2005 Feb 24;352(8):793-803 - PubMed
  5. Med Clin North Am. 2009 Nov;93(6):1183-94 - PubMed
  6. J Invest Dermatol. 1998 Nov;111(5):864-72 - PubMed
  7. J Eur Acad Dermatol Venereol. 2015 Dec;29(12 ):2405-10 - PubMed
  8. J Am Acad Dermatol. 2010 Jul;63(1):33-9 - PubMed
  9. Contact Dermatitis. 2015 Dec;73(6):366-7 - PubMed
  10. J Drugs Dermatol. 2013 Jun 1;12(6):650-6 - PubMed
  11. J Drugs Dermatol. 2016 Jun 1;15(6):763-5 - PubMed
  12. J Dermatol Sci. 2009 Aug;55(2):77-81 - PubMed
  13. J Investig Dermatol Symp Proc. 2011 Dec;15(1):2-11 - PubMed
  14. J Invest Dermatol. 2012 Apr;132(4):1253-62 - PubMed
  15. J Am Acad Dermatol. 2014 Feb;70(2):e37-8 - PubMed
  16. J Clin Aesthet Dermatol. 2012 Mar;5(3):16-25 - PubMed
  17. Cochrane Database Syst Rev. 2011 Mar 16;(3):CD003262 - PubMed
  18. J Biol Chem. 1996 Sep 6;271(36):21793-7 - PubMed
  19. J Drugs Dermatol. 2014 Jan;13(1):56-61 - PubMed
  20. Arch Dermatol. 2010 Aug;146(8):896-902 - PubMed
  21. J Am Acad Dermatol. 2014 Oct;71(4):832-3 - PubMed
  22. J Investig Dermatol Symp Proc. 2011 Dec;15(1):33-9 - PubMed
  23. J Am Acad Dermatol. 2002 Apr;46(4):584-7 - PubMed
  24. J Am Acad Dermatol. 2014 May;70(5):e109-10 - PubMed
  25. J Eur Acad Dermatol Venereol. 2010 May;24(5):565-71 - PubMed
  26. Clin Cosmet Investig Dermatol. 2015 Oct 23;8:529-38 - PubMed
  27. Br J Dermatol. 1998 Feb;138(2):221-4 - PubMed
  28. Nat Med. 2007 Aug;13(8):975-80 - PubMed
  29. Br J Dermatol. 2012 Mar;166(3):633-41 - PubMed
  30. J Drugs Dermatol. 2014 Jun;13(6):699-704 - PubMed

Publication Types